ASH 2017 top picks: Phase III trials, antibody-drug conjugates and CAR T-cells
How is the landscape of Hodgkin lymphoma therapy changing?
Finding novel treatment options for relapsed/progressing AML
Copanlisib for relapsed/refractory NHL: results of the CHRONOS-1 study
Highlights from the International Symposium on Acute Leukemias (ISAL) 2017 in Munich